ELVIRA DEOLINDA RODRIGUES PEREIRA VELLOSO
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Clínica Médica, Faculdade de Medicina - Docente
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina
13 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 13
- Duffy null genotype or Fy(a-b-) phenotype are more accurate than self-declared race for diagnosing benign ethnic neutropenia in Brazilian population(2017) DINARDO, C. L.; KERBAUY, M. N.; SANTOS, T. C.; LIMA, W. M.; DEZAN, M. R.; OLIVEIRA, V. B.; MENDRONE-JUNIOR, A.; ROCHA, V.; VELLOSO, E. D. R. P.
conferenceObject Morphological, Immunohistochemical and Cytogenetic Bone Marrow Characterization of 12 Patients with Acquired Aplastic Anemia (AAA) That Progressed to Myelodysplastic Syndromes (MDS)(2017) MARCHESI, Raquel; VELLOSO, Elvira; GARANITO, Marlene; SIQUEIRA, Sheila; NETO, Raymundo Azevedo; KUMEDA, Cristina; ZERBINI, Maria Claudia- Secondary myeloid neoplasms: bone marrow cytogenetic and histological features may be relevant to prognosis(2017) TANIZAWA, Roberta Sandra da Silva; ZERBINI, Maria Claudia Nogueira; ROSENFELD, Ricardo; KUMEDA, Cristina Aiko; AZEVEDO, Raymundo Soares; SIQUEIRA, Sheila Aparecida Coelho; VELLOSO, Elvira Deolinda Rodrigues PereiraAbstract Background: Secondary myeloid neoplasms comprise a group of diseases arising after chemotherapy, radiation, immunosuppressive therapy or from aplastic anemia. Few studies have addressed prognostic factors in these neoplasms. Method: Forty-two patients diagnosed from 1987 to 2008 with secondary myeloid neoplasms were retrospectively evaluated concerning clinical, biochemical, peripheral blood, bone marrow aspirate, biopsy, and immunohistochemistry and cytogenetic features at diagnosis as prognostic factors. The International Prognostic Scoring System was applied. Statistical analysis employed the Kaplan–Meier method, log-rank and Fisher's exact test. Results: Twenty-three patients (54.8%) were male and the median age was 53.5 years (range: 4–88 years) at diagnosis of secondary myeloid neoplasms. Previous diseases included hematologic malignancies, solid tumors, aplastic anemia, autoimmune diseases and conditions requiring solid organ transplantations. One third of patients (33%) were submitted to chemotherapy alone, 2% to radiotherapy, 26% to both modalities and 28% to immunosuppressive agents. Five patients (11.9%) had undergone autologous hematopoietic stem cell transplantation. The median latency between the primary disease and secondary myeloid neoplasms was 85 months (range: 23–221 months). Eight patients were submitted to allogeneic hematopoietic stem cell transplantation to treat secondary myeloid neoplasms. Important changes in bone marrow were detected mainly by biopsy, immunohistochemistry and cytogenetics. The presence of clusters of CD117+ cells and p53+ cells were associated with low survival. p53 was associated to a higher risk according to the International Prognostic Scoring System. High prevalence of clonal abnormalities (84.3%) and thrombocytopenia (78.6%) were independent factors for poor survival. Conclusion: This study demonstrated that cytogenetics, bone marrow biopsy and immunohistochemistry are very important prognostic tools in secondary myeloid neoplasms.
- RESULTS OF THE LATIN-AMERICAN REGISTRY OF BONE MARROW TRANSPLANTATION (BMT) IN MYELODYSPLASTIC SYNDROME (MDS)(2017) DUARTE, F.; SANTOS, T. E. J.; FUNKE, V. A. M.; COLTURATO, V. A. R. C.; HAMERSCHLAK, N.; VILELA, N. C. V.; LOPES, L. F.; MACEDO, M. C. M. A.; VIGORITO, A. C.; SOARES, R. D. D. A.; PAZ, A.; STEVENAZZI, M.; DIAZ, L.; NETO, A. E. H. N.; BETTARELLO, G.; GUSMAO, B. M.; SALVINO, M. A.; CALIXTO, R. F.; VELLOSO, E. D. R. P.; LEMES, R. P. G.
conferenceObject High Proliferative Index in Acquired Aplastic Anemia (AAA) Bone Marrow Does Not Predict Progression to Myelodysplastic Syndromes (MDS)(2017) MARCHESI, Raquel; VELLOSO, Elvira; GARANITO, Marlene; SIQUEIRA, Sheila; NETO, Raymundo Azevedo; KUMEDA, Cristina; ZERBINI, Maria Claudia- Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome(2017) SILVA, Fernanda Borges Da; MACHADO-NETO, Joao Agostinho; BERTINI, Virginia Helena Leira Lipoli; VELLOSO, Elvira Deolinda Rodrigues Pereira; RATIS, Cristina Alonso; CALADO, Rodrigo T.; SIMOES, Belinda Pinto; REGO, Eduardo Magalhaes; TRAINA, FabiolaAims The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal haematopoietic stem cell disorders characterised by inefficient haematopoiesis and risk of progression to acute myeloid leukaemia. Metaphase cytogenetics is an extremely valuable clinical tool in the management of haematological malignancies. However, metaphase cytogenetics requires cellular proliferation, its sensitivity and resolution depends on the proportion of clonal cells in the sample and size of the lesion, respectively. Single-nucleotide polymorphism array (SNP-A) does not depend on the presence of dividing cells, is able to detect copy number variations with a high resolution and to detect copy number neutral loss of heterozygosity or uniparental disomy (UPD). The aim of this study was to illustrate that the use of SNP-A can cover cryptic chromosomal lesions not identified by metaphase cytogenetics in patients with MDS. Methods Metaphase cytogenetics was performed on bone marrow aspirate using standard methods. Genomic DNA from total bone marrow cells were submitted to SNP-A using Affymetrix Genome-Wide Human SNP CytoScan HD. Results In our cohort of 15 patients with a diagnosis of MDS and related diseases, chromosomal abnormalities were found in 47% of the cases by SNP-A and in 33% by metaphase cytogenetics. SNP-A detected all lesions identified by metaphase cytogenetics, except a balanced translocation and a marker chromosome. Notably, SNP-A detected a total of 30 new lesions: 1 (3%) gain, 17 (57%) losses and 12 (40%) UPDs in 5 patients with MDS. Conclusions SNP-A may complement metaphase cytogenetics to improve the detection of chromosomal abnormalities in myeloid neoplasms.
- Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib(2017) CAMPREGHER, Paulo Vidal; HALLEY, Nathalia da Silva; VIEIRA, Gabriela Amaral; FERNANDES, Juliana Folloni; VELLOSO, Elvira Deolinda Rodrigues Pereira; ALI, Siraj; MUGHAL, Tariq; MILLER, Vincent; MANGUEIRA, Cristovao Luis Pitangueira; ODONE, Vicente; HAMERSCHLAK, Nelson
conferenceObject High Proliferative Index in Acquired Aplastic Anemia (AAA) Bone Marrow Does Not Predict Progression to Myelodysplastic Syndromes (MDS)(2017) MARCHESI, Raquel; VELLOSO, Elvira; GARANITO, Marlene; SIQUEIRA, Sheila; NETO, Raymundo Azevedo; KUMEDA, Cristina; ZERBINI, Maria ClaudiaconferenceObject Morphological, Immunohistochemical and Cytogenetic Bone Marrow Characterization of 12 Patients with Acquired Aplastic Anemia (AAA) That Progressed to Myelodysplastic Syndromes (MDS)(2017) MARCHESI, Raquel; VELLOSO, Elvira; GARANITO, Marlene; SIQUEIRA, Sheila; NETO, Raymundo Azevedo; KUMEDA, Cristina; ZERBINI, Maria Claudia- RELEVANCE OF CYTOGENETICS IN MYELODYSPLASTIC SYNDROME (MDS) IN THE ASSESSMENT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) SURVIVAL(2017) DUARTE, F.; SANTOS, T. E. J.; KORHNBLITT, L.; CORREA, W.; BASQUIERA, A. L.; BELLI, C.; FUNKE, V. A. M.; COLTURATO, V. A. R.; HAMERSCHLAK, N.; VILELA, N. C.; SILVA, R. L.; VIGORITO, A. C.; PAZ, A.; STEVENAZZI, M.; VELLOSO, E.; HALLACK NETO, A. E.; BETTARELLO, G.; LOPES, L. F.; SOARES, R. D. D. A.; LEMES, R. P. G.